Homo sapiens met proto-oncogene (hepatocyte growth factor receptor) (MET), transcript variant 2
Synonyms:
AUTS9; c-Met; HGFR; RCCP2
Immunogen
A synthetic peptide corresponding to residues near the N-terminus of human Met was used as an immunogen.
Buffer
50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.
Clone Name
EP1454Y
Isotype
IgG
Species Reactivity
Human
Concentration
Purification
Guaranteed Application *
WB, IHC
Suggested Dilutions
WB (1:2000); IHC (1:100 250); ICC (1:100 250)
Background
Met is a receptor protein-tyrosine kinase (RPTK) for hepatocyte growth factor (HGF), which is a multifunctional cytokine controlling cell growth, morphogenesis, and motility. Met overexpression has been identified in a variety of human cancers (1). Met kinase domain possesses unique features that distinguish met from other members of the src family of protein tyrosine kinases. These results also demonstrate that the product of the activated met gene is a fusion protein and that the amino terminal end of this fusion protein exhibits homology to laminin B1 (2). Data suggest that RanBP9, functioning as an adaptor protein for the Met tyrosine kinase domain, can augment the HGF-Met signaling pathway and that RanBP9 overexpression may cause constitutive activation of the Ras signaling pathway (1). Hereditary papillary renal carcinoma (HPRC) is a recently recognized form of inherited kidney cancer Results suggest that missense mutations located in the MET proto-oncogene lead to constitutive activation of the Met protein and papillary renal carcinomas (3)
Related Pathway
Adherens junction
Cytokine-cytokine receptor interaction
Focal Adhesion
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
